GMDP academy
ISSUE 66 • JULY 18, 2025

ACADEMY LEADER HONORED WITH FPM'S HIGHEST AWARD

The GMDP Academy proudly celebrates Professor Sam Salek — Program Director, Academic Committee Head, and Module 5 Chair — as the recipient of the 2025 President's Medal from the Faculty of Pharmaceutical Medicine, the highest individual honor awarded by the FPM.

Turn to page 2 to read more about this outstanding recognition and Professor Salek's global impact on pharmaceutical medicine education.

TABLE OF CONTENTS

Professor Sam Salek receiving the President's Medal at the Annual Awards Ceremony with FPM President, Dr Sheuli Porkess. Courtesy of FPM.

Top Center: FPM Awards Ceremony Attendees. Photo Courtesy of Sam Salek
Bottom Right: Professor Salek stands between FPM President, Dr. Sheuli Porkess and nominator, Professor Peter Stonier Photo Courtesy of FPM

PROFESSOR SAM SALEK RECEIVES FACULTY OF PHARMACEUTICAL MEDICINE PRESIDENT'S MEDAL

The 2025 President's Medal award is presented annually to an individual whose work has made a significant and lasting impact on the field of pharmaceutical medicine. Professor Salek received the award at this year's Annual Awards Ceremony following a competitive nomination and selection process. His contributions to education, training, and the advancement of professional standards have spanned decades. Nominator Dr. Peter Stonier described Professor Salek's legacy:

"Sam's pioneering record over 40 years of contribution and influence in the development and sustainability of full E&T in pharmaceutical medicine is unequalled, whether at home now as Professor of Pharmacoepidemiology & Regulatory Science at University of Hertfordshire or leading and contributing to programmes in Europe, Africa and other regions around the world."

GMDP Academy is proud to support and benefit from Professor Salek's ongoing commitment to advancing the field of pharmaceutical medicine.

Read more here.

MODULE 7: LEADERSHIP IN MEDICINES DEVELOPMENT

Dates: September 29 – November 21, 2025

Tuition: $3,000 USD

Weekly Commitment: 3–5 hours

Final Assessment Due: December 1, 2025

Build confidence and competence in your leadership style through interactive webinars and real-world application. Topics include courageous leadership, thought leadership, change management, and resilience. The module culminates in a personalized Leadership Action Plan.

MODULE 8: DIGITAL TECHNOLOGY IN MEDICINES DEVELOPMENT

Dates: September 29 – November 9, 2025 (Orientation begins Sept 22)

Tuition: $3,000 USD

Weekly Commitment: ~5 hours

Learn how digital tools are reshaping R&D, clinical trials, communication, regulation, and patient engagement. This 8-lesson module includes 2 expert-led webinars and covers topics such as digital ethics, risk management, emerging technology, and patient-centered design.

💡 NOW ENROLLING

- 100% online and globally accessible
- World-class speakers and interactive learning
- Certificate of Completion from GMDP Academy
- Perfect for professionals in Medical Affairs, R&D, Regulatory, Clinical, and Digital Health

📌 Apply by September 15, 2025 to reserve your seat and lead the future of pharma.

👉 Start Your Application

ACCELERATING INNOVATION: EMBRACING AI TO REDUCE CYCLE TIMES IN DRUG DEVELOPMENT

Clinical trials are taking longer and becoming more expensive, largely due to increasing complexity and massive data demands. Between 2010 and 2020, Phase III trials saw a 283% rise in data volume with consequences such as longer timelines and higher costs across the board.

Through avenues such as predictive recruitment, automated data analysis, and smarter protocol design, AI and machine learning are poised to transform this process. But adoption across systems has been slow.

By providing technical training on the effective application of AI and digital technologies, GMDP Academy's Module 8: Digital Technologies in Medicines Development, aims to help professionals close the gap between potential and practice.

Read more about how AI can help reduce clinical trial timelines, and how the Academy's Module 8 prepares professionals to be at the forefront of this shift. [1,2,3] 👉 Read the full article.

HOW AI AND SINGLE-CELL GENOMICS ARE REWRITING BIOMEDICAL DISCOVERY

In another innovative example of how pharma is integrating AI and computational biology into research and development, the Arc Institute's Virtual Cell Atlas uses AI and single-cell data to simulate cellular behavior across time, treatment, and tissue types. There are over 400 million cells mapped so far. Data sets like Tahoe-100M, with data from over 100 million individual cells capture how each individual cell responds to a specific treatment.

This has huge implications for the intersection of AI and drug discovery. [4,5,6]
👉 Read the full article.

WHAT IT MEANS TO BE A CMD-CERTIFIED PROFESSIONAL: SHAPING THE FUTURE OF MEDICINES DEVELOPMENT

What sets CMD-Certified Professionals apart?

From early discovery to regulatory approval and patient access, CMD professionals are trained across the entire lifecycle of medicines. But it's about more than essential knowledge and a title. Beyond the title, it signals a commitment to evidence-based decision-making, strategic leadership, and collaborative innovation across the entire medicines lifecycle.

Defining the CMD Credential

The CMD is a 10-month, interdisciplinary certification developed with King's College London. Participants complete six core modules and an optional leadership track, gaining expertise in translational science, trial design, regulatory strategy, HEOR, and ethical stakeholder engagement.

CMD Graduates Bring:

🔬 **Scientific and Regulatory Expertise**
Deep knowledge of pharmacology, clinical trials, and global regulatory systems.

💬 **Strategic Communication Skills**
The ability to translate data into insights for regulators, clinicians, and patients.

📊 **Health Economics & Policy Understanding**
Insight into the cost-effectiveness, ethics, and societal impact of medicines.

🤝 **Leadership and Collaboration**
Skills in cross-functional teamwork and systems thinking.

🌍 **Ethical, Global Perspective and Decision-Making**
A strong commitment to patient safety, transparency, and health equity.

Why CMD Matters Now:

From early discovery to regulatory approval and patient access, CMD professionals are trained across the entire lifecycle of medicines. But it's about more than essential knowledge and a title. Beyond the title, it signals a commitment to evidence-based decision-making, strategic leadership, and collaborative innovation across the entire medicines lifecycle.

🌐 Learn more here.

WHEN INNOVATION WAITS: CONFRONTING EUROPE'S UNEQUAL ACCESS TO MEDICINES

New data from EFPIA paints a troubling picture: on average, it takes 578 days for patients in Europe to access a newly approved medicine. In Germany, the wait is around four months. In Portugal, it can stretch to nearly two and a half years.

These delays aren't about science, they're about systems. Medicines are approved centrally through the EMA, but decisions on pricing and reimbursement are left to national authorities. This creates fragmentation and inconsistency with processes and timelines. Unfortunately, patients pay the price. The solution requires professionals and policy that do more than tweak technical aspects of the problem, but that also reflect understanding of the complexities in access.

It's also an educational challenge.

Through the Academy's CMD and modular training in regulatory strategy, market access, health economics, and medical affairs, we are preparing professionals for precisely these challenges.[7,8,9] 👉 Read more here.

POST-APPROVAL RESEARCH AND THE EDUCATIONAL IMPERATIVE IN MEDICINES DEVELOPMENT

Post-approval research and surveillance are essential to understanding how medicines work in the real world—but they're often overlooked in policy and underfunded in practice. Weak enforcement, fragmented data systems, and regulatory gaps leave patients at risk and innovation underutilized.

At GMDP Academy, we train professionals to lead across the full lifecycle of medicines. Our Certification in Medicines Development, including modules like Regulatory Affairs & Drug Safety and Medical Affairs as a Strategic Business Partner, prepares graduates to drive post-approval strategy, safety, and access.[10-16]

👉 Read more here.

HOW GMDP ACADEMY IS EMPOWERING GLOBAL PROFESSIONALS IN A RAPIDLY CHANGING FIELD

The Academy can play a crucial role by offering flexible, forward-looking training programs—combining basic knowledge with emerging tools... promoting lifelong learning and encouraging more cross-disciplinary collaboration. Therefore, the Academy can empower professionals to stay current, confident, and impactful in their roles.

Dr. Xavier Luria
Chair of the GMDP Academy Board

INSIGHTS FROM DR. XAVIER LURIA

In a conversation with Dr. Xavier Luria, recently appointed Chair of the GMDP Academy Board, we explored his vision for the Academy's future and its evolving role in global medicines development.

A longtime contributor and internationally respected regulatory expert, Dr. Luria emphasized the need for modern, flexible education to keep pace with rapid advancements in science, technology, and regulation.

As Chair, Dr. Luria outlined three key priorities:

- **Innovation**: Integrate cutting-edge science, digital tools, and regulatory trends into the curriculum.
- **Inclusivity**: Expand access for professionals across regions, backgrounds, and career stages.
- **Global Impact**: Strengthen partnerships with regulators, academia, and industry to shape future practice and policy.

🎥 Watch the full interview **here**

REFERENCES

1. Indupuri, R. (2025, May 20). Cycle time is the new currency of drug development. HIT Consultant. https://hitconsultant.net/2025/05/20/cycle-time-is-the-new-currency-of-drug-development/
2. Tufts Center for the Study of Drug Development. (2021). Rising protocol design complexity is driving rapid growth in clinical trial data volume. https://f.hubspotusercontent10.net/hubfs/9468915/TuftsCSDD_June2021/pdf/Rising%2BProtocol%2BDesign%2BComplexity.pdf
3. Getz, K. (2024). Tufts CSDD: New insights on the clinical trial industry. Clinical Trial Vanguard. https://www.clinicaltrialvanguard.com/conference-coverage/tufts-csdd-new-insights-on-the-clinical-trial-industry/
4. Arc Institute. (2025, February). Arc Virtual Cell Atlas launches, combining data from over 300 million cells. https://arcinstitute.org/news/news/arc-virtual-cell-atlas-launch
5. Grinstein, J. D. (2025, April 28). Arc Institute teams with 10x and Ultima Genomics to evolve virtual cell atlas. Inside Precision Medicine. https://www.insideprecisionmedicine.com
6. Zhang, J., Ubas, A. A., de Borja, R., Svensson, V., et al. (2025). Tahoe-100M: A giga-scale single-cell perturbation atlas for context-dependent gene function and cellular modeling. bioRxiv. https://doi.org/10.1101/2025.02.20.639398
7. European Federation of Pharmaceutical Industries and Associations (EFPIA). (2025). New data shows no shift in access to medicines for millions of Europeans. https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/new-data-shows-no-shift-in-access-to-medicines-for-millions-of-europeans
8. CRA & EFPIA. (2025). Root causes of unavailability and delay to innovative medicines. https://www.efpia.eu/media/602581
9. GMDP Academy. (2024). GMDP Academy Offerings 2024–2025. https://info.gmdpacademy.org/course-catalog
10. Axelsen, K., & Miller, B. J. (2025, May 19). Modeling drug development: Improvements still needed. AEIdeas. https://www.aei.org/health-care/modeling-drug-development-improvements-still-needed/
11. Cooley LLP. (2023, January 31). FDORA changes to the FDA Accelerated Approval Program. https://www.cooley.com/news/insight/2023/2023-01-31-fdora-changes-to-the-fda-accelerated-approval-program
12. Lindus Health. (2024). Understanding clinical phase 4 post-market surveillance and its importance. https://www.lindushealth.com/blog/understanding-clinical-phase-4-post-market-surveillance-and-its-importance
13. Oncology News Central. (2024). FDA urged to levy fines for delayed confirmatory trials in oncology and beyond. https://www.oncologynewscentral.com/article/fda-urged-to-levy-fines-for-delayed-confirmatory-trials-in-oncology-and-beyond
14. Pharmacovigilance. (2024). In Wikipedia. https://en.wikipedia.org/wiki/Pharmacovigilance
15. Silva, H., Stonier, P. D., Kerpel-Fronius, S., & Dubois, D. J. (2021). Editorial: Grand challenges in pharmaceutical medicine: Competencies and ethics in medicines development. Frontiers in Pharmacology, 12, 666406. https://doi.org/10.3389/fphar.2021.666406:contentReference[oaicite:2]{index=2}
16. Silva, H., Stonier, P., Chopra, P., et al. (2024). Blended e-learning and certification for medicines development professionals: Results of a 7-year collaboration between King's College, London and the GMDP Academy, New York. Frontiers in Pharmacology, 15, 1417036. https://doi.org/10.3389/fphar.2024.1417036:contentReference[oaicite:3]{index=3}

Thanks for reading!

The GMDP Academy Newsletter is published twice monthly and is compiled by the following:

Media Manager: Whitney English

Editorial Board: Pravin Chopra, Jacob Coots

Operations Office: Amanda Schmitt, Gustavo Silva, Kit Vale

CONTACT US:

420 Lexington Ave. Ste. 300
New York, NY 10170

(332) 333-2438